7.065
price down icon7.34%   -0.545
 
loading
Altimmune Inc stock is traded at $7.065, with a volume of 3.50M. It is down -7.34% in the last 24 hours and up +2.49% over the past month. Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
See More
Previous Close:
$7.61
Open:
$7.55
24h Volume:
3.50M
Relative Volume:
1.32
Market Cap:
$519.17M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-4.3344
EPS:
-1.63
Net Cash Flow:
$-71.49M
1W Performance:
-4.06%
1M Performance:
+2.49%
6M Performance:
-11.97%
1Y Performance:
+188.99%
1-Day Range:
Value
$6.945
$7.59
1-Week Range:
Value
$6.945
$11.16
52-Week Range:
Value
$2.41
$14.84

Altimmune Inc Stock (ALT) Company Profile

Name
Name
Altimmune Inc
Name
Phone
(240) 654-1450
Name
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Name
Employee
59
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
ALT's Discussions on Twitter

Compare ALT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ALT 7.065 519.17M 409.00K -101.35M -71.49M -1.63
VRTX 467.45 119.83B 10.63B -479.80M -1.35B 13.33
REGN 760.78 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.72 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.44 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.44 24.08B 3.30B -501.07M 1.03B 11.54

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-29-24 Downgrade Guggenheim Buy → Neutral
Jan-24-24 Initiated Goldman Neutral
Mar-22-23 Downgrade Goldman Buy → Neutral
Dec-01-22 Initiated Goldman Buy
Dec-29-21 Resumed Jefferies Buy
Jun-02-21 Initiated H.C. Wainwright Buy
Feb-11-21 Initiated Guggenheim Buy
Dec-14-20 Initiated Jefferies Buy
Nov-12-20 Reiterated B. Riley Securities Buy
Sep-25-20 Initiated B. Riley FBR Buy
Aug-14-20 Initiated Evercore ISI Outperform
Jul-31-20 Initiated Piper Sandler Overweight
Jul-28-20 Initiated JMP Securities Mkt Outperform
Feb-24-20 Resumed ROTH Capital Buy
Jul-19-19 Initiated ROTH Capital Buy
Oct-09-17 Initiated Piper Jaffray Overweight
View All

Altimmune Inc Stock (ALT) Latest News

pulisher
02:52 AM

HC Wainwright Decreases Earnings Estimates for Altimmune - MarketBeat

02:52 AM
pulisher
01:54 AM

Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

01:54 AM
pulisher
Nov 16, 2024

(ALT) Trading Report - Stock Traders Daily

Nov 16, 2024
pulisher
Nov 15, 2024

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - The Manila Times

Nov 15, 2024
pulisher
Nov 15, 2024

Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 - Marketscreener.com

Nov 15, 2024
pulisher
Nov 15, 2024

What is B. Riley's Forecast for Altimmune FY2024 Earnings? - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

B. Riley Weighs in on Altimmune's Q1 Earnings (NASDAQ:ALT) - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Altimmune (NASDAQ:ALT) Given Buy Rating at HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Altimmune Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge (NASDAQ:ALT) - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune Unusual Options Activity For November 13 - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune’s Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health (ALT) - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune provided key pipeline updates with Q3 report, says B. Riley - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

UBS Initiates Coverage of Altimmune (ALT) with Buy Recommendation - Nasdaq

Nov 13, 2024
pulisher
Nov 13, 2024

GSA Capital Partners LLP Sells 148,530 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Altimmune reports progress on pemvidutide trials, financials - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Earnings call: Altimmune reports progress on pemvidutide trials, financials By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding R&D Investments - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Altimmune (ALT) Stock Soars 27%: Phase 2 Data On Obesity Drug Ignites Market Optimism - Barchart

Nov 13, 2024
pulisher
Nov 12, 2024

Altimmune Reports Q3 2024 Financial Results and Advances Drug Pipeline - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune Stock Rallies 30% on Updates - citybiz

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune stock rallies 30% on business updates, UBS buy rating - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune stock rallies 30% on business updates, UBS buy rating (NASDAQ:ALT) - Seeking Alpha

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Traders Purchase Large Volume of Altimmune Call Options (NASDAQ:ALT) - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune Inc Reports Q3 2024 Results: GAAP EPS of -$0.32 Beats Estimates, Revenue at $5,000 - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune Appoints Gregory Weaver as CFO for Growth - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

UBS Group Initiates Coverage on Altimmune (NASDAQ:ALT) - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update - Yahoo Finance

Nov 12, 2024
pulisher
Nov 11, 2024

Altimmune Appoints Greg Weaver as CFO - citybiz

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune Appoints Chief Financial Officer - Contract Pharma

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune says ‘something raised attention of FDA’ - TipRanks

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune appoints Greg Weaver as CFO - TipRanks

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune Names Greg Weaver Chief Financial Officer - MarketWatch

Nov 11, 2024
pulisher
Nov 11, 2024

S&P 500 Index (INX) QuotePress Release - The Globe and Mail

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail

Nov 11, 2024
pulisher
Nov 11, 2024

Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer - Marketscreener.com

Nov 11, 2024
pulisher
Nov 08, 2024

How Altimmune Could Grab a Big Chunk of the GLP-1 Market - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Eli Lilly and Company (LLY-N) QuotePress Release - The Globe and Mail

Nov 08, 2024
pulisher
Nov 08, 2024

Institutional investors control 59% of Altimmune, Inc. (NASDAQ:ALT) and were rewarded last week after stock increased 11% - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

Altimmune advances obesity treatment into Phase 3 trials By Investing.com - Investing.com South Africa

Nov 08, 2024
pulisher
Nov 07, 2024

Altimmune, FDA agree on efficacy measures for phase 3 trial of pemvidutide - Seeking Alpha

Nov 07, 2024
pulisher
Nov 07, 2024

Altimmune advances obesity treatment into Phase 3 trials - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Altimmune Advances Obesity Drug: FDA Greenlights Major Phase 3 Program Design | ALT Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times

Nov 06, 2024

Altimmune Inc Stock (ALT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Altimmune Inc Stock (ALT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Drutz David
Director
Aug 19 '24
Sale
6.90
16,011
110,547
41,958
Roberts M Scot
Chief Scientific Officer
Feb 02 '24
Option Exercise
0.00
7,775
0
44,990
Roberts M Scot
Chief Scientific Officer
Feb 01 '24
Option Exercise
0.00
6,166
0
39,016
Harris Matthew Scott
Chief Medical Officer
Feb 02 '24
Option Exercise
0.00
7,775
0
55,965
Harris Matthew Scott
Chief Medical Officer
Feb 01 '24
Option Exercise
0.00
6,166
0
49,991
Garg Vipin K
President and CEO
Feb 02 '24
Option Exercise
0.00
18,950
0
300,404
Garg Vipin K
President and CEO
Feb 01 '24
Option Exercise
0.00
16,545
0
288,767
Roberts M Scot
Chief Scientific Officer
Jan 30 '24
Option Exercise
0.00
9,275
0
29,699
Harris Matthew Scott
Chief Medical Officer
Jan 30 '24
Option Exercise
0.00
9,275
0
43,277
Garg Vipin K
President and CEO
Jan 30 '24
Option Exercise
0.00
26,775
0
276,030
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.25
price down icon 0.96%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):